CureVac/$CVAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CureVac
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Ticker
$CVAC
Sector
Primary listing
Employees
904
Headquarters
Website
CureVac Metrics
BasicAdvanced
$1.2B
5.46
$0.99
2.53
-
Price and volume
Market cap
$1.2B
Beta
2.53
52-week high
$5.72
52-week low
$2.37
Average daily volume
785K
Financial strength
Current ratio
6.172
Quick ratio
5.887
Long term debt to equity
5.312
Total debt to equity
6.145
Interest coverage (TTM)
589.30%
Profitability
EBITDA (TTM)
288.086
Gross margin (TTM)
94.85%
Net profit margin (TTM)
37.93%
Operating margin (TTM)
46.40%
Effective tax rate (TTM)
12.14%
Revenue per employee (TTM)
$648,760
Management effectiveness
Return on assets (TTM)
23.77%
Return on equity (TTM)
40.22%
Valuation
Price to earnings (TTM)
5.462
Price to revenue (TTM)
2.06
Price to book
2.08
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
5.362
Free cash flow yield (TTM)
18.65%
Free cash flow per share (TTM)
1.011
Growth
Revenue change (TTM)
675.15%
Earnings per share change (TTM)
-168.74%
3-year revenue growth (CAGR)
64.31%
3-year earnings per share growth (CAGR)
-9.85%
What the Analysts think about CureVac
Analyst ratings (Buy, Hold, Sell) for CureVac stock.
CureVac Financial Performance
Revenues and expenses
CureVac Earnings Performance
Company profitability
CureVac News
AllArticlesVideos
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
Accesswire·1 week ago
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
Proactive Investors·2 weeks ago
CureVac settles patent dispute litigation with Pfizer and BioNTech
Reuters·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CureVac stock?
CureVac (CVAC) has a market cap of $1.2B as of August 22, 2025.
What is the P/E ratio for CureVac stock?
The price to earnings (P/E) ratio for CureVac (CVAC) stock is 5.46 as of August 22, 2025.
Does CureVac stock pay dividends?
No, CureVac (CVAC) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next CureVac dividend payment date?
CureVac (CVAC) stock does not pay dividends to its shareholders.
What is the beta indicator for CureVac?
CureVac (CVAC) has a beta rating of 2.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.